Literature DB >> 1388895

Levels of pyrimethamine in serum and penetration into brain tissue in humans.

C Leport, A Meulemans, D Robine, G Dameron, J L Vildé.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1388895     DOI： 10.1097/00002030-199209000-00021

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  10 in total

1.  Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii.

Authors:  J M Jacobson; M Davidian; P M Rainey; R Hafner; R H Raasch; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs.

Authors:  M Viora; A De Luca; A D'Ambrosio; A Antinori; E Ortona
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS.

Authors:  H Klinker; P Langmann; E Richter
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Authors:  Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

5.  Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine.

Authors:  E Schoondermark-van de Ven; J Galama; T Vree; W Camps; I Baars; T Eskes; J Meuwissen; W Melchers
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 6.  Disseminated toxoplasmosis in non-allografted patients with hematologic malignancies: report of two cases and literature review.

Authors:  S Scerra; H Coignard-Biehler; F Lanternier; F Suarez; C Charlier-Woerther; M-E Bougnoux; J Gilquin; M Lecuit; O Hermine; O Lortholary
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-18       Impact factor: 3.267

7.  Azithromycin for ocular toxoplasmosis.

Authors:  A Rothova; L E Bosch-Driessen; N H van Loon; W F Treffers
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

Review 8.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

9.  Fulminant and Diffuse Cerebral Toxoplasmosis as the First Manifestation of HIV Infection: A Case Presentation and Review of the Literature.

Authors:  Salman Abbasi Fard; Ali Khajeh; Alireza Khosravi; Afsaneh Mirshekar; Safoora Masoumi; Farhad Tabasi; Tania Hassanzadeh; Martin M Mortazavi
Journal:  Am J Case Rep       Date:  2020-01-26

10.  Successful Treatment of Cerebral Toxoplasmosis Using Pyrimethamine Oral Solution Compounded From Inexpensive Bulk Powder.

Authors:  Hayley A Hodgson; Taeyong Sim; Hemil Gonzalez; Mariam Aziz; Yoona Rhee; Paul O Lewis; Neel Jhobalia; Beth Shields; Sheila K Wang
Journal:  Open Forum Infect Dis       Date:  2018-04-18       Impact factor: 3.835
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.